Browsed by
Tag: Drug

Covid-19 Vaccines Offer Drug Makers Chance at Salvation, Financial and Beyond

Covid-19 Vaccines Offer Drug Makers Chance at Salvation, Financial and Beyond

For a long time, drug makers have been the most hated industry in America. Companies are blamed for gouging prices on lifesaving drugs and enriching themselves through the opioid crisis, among other sins.

Now, with pharmaceutical companies racing to find vaccines to end the coronavirus pandemic, the industry is hoping to redeem itself in the public’s mind.

The primary goal, of course, is to rescue the world from the grips of a vicious virus. But a big fringe benefit is to get public credit — and to use an improved image to fend off government efforts to more heavily regulate the industry.

Consider Johnson & Johnson, one of the world’s largest health care companies.

In recent years, its reputation has been battered by accusations that products like its artificial hips and talcum powder have harmed customers. In 2019, an Oklahoma judge ordered the company to pay $572 million for contributing to the opioid epidemic.

This spring, Johnson & Johnson jumped into the hunt for a Covid-19 vaccine; its candidate is now in the final stage of clinical trials. (On Monday, the company said it had temporarily paused the study after a participant became sick with an unexplained illness.)

Regardless of whether the vaccine ever comes to market, the company is looking to create a surge of positive publicity from its work. Its chief executive, Alex Gorsky, went on the “Today” show this spring and called Johnson & Johnson’s lab workers heroes. The company has produced a slick, self-promotional online video series, “The Road to a Vaccine,” featuring feel-good interviews with the company’s scientists and segments on issues like whether it is safe to send children back to school.

Johnson & Johnson’s efforts to develop a vaccine will show that “J&J is a company full of people with heart and soul

Read the rest
Global Optic Neuropathy Pipeline Review 2020: Therapeutic Analysis of 8 Companies & 4 Drug Profiles

Global Optic Neuropathy Pipeline Review 2020: Therapeutic Analysis of 8 Companies & 4 Drug Profiles

DUBLIN–(BUSINESS WIRE)–Oct 13, 2020–

The “Optic Neuropathy – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Optic Neuropathy – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Optic Neuropathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Optic Neuropathy (Ophthalmology) pipeline guide also reviews the key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 2, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Optic Neuropathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Optic Neuropathy (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Optic Neuropathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Optic Neuropathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Optic Neuropathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug
Read the rest
Global Encephalomyelitis Pipeline Review 2020: Therapeutic Analysis Report Featuring 7 Companies & 5 Drug Profiles

Global Encephalomyelitis Pipeline Review 2020: Therapeutic Analysis Report Featuring 7 Companies & 5 Drug Profiles

DUBLIN–(BUSINESS WIRE)–Oct 13, 2020–

The “Encephalomyelitis – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Encephalomyelitis – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Encephalomyelitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalomyelitis (Central Nervous System) pipeline guide also reviews the key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, IND/CTA Filed and Preclinical stages are 1, 2, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Encephalomyelitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalomyelitis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Encephalomyelitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Encephalomyelitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Encephalomyelitis (Central Nervous System) therapeutics based on
Read the rest
COVID-19 drug developer Atea Pharmaceuticals files for IPO (NASDAQ:GILD)

COVID-19 drug developer Atea Pharmaceuticals files for IPO (NASDAQ:GILD)

Atea Pharmaceuticals has filed for its initial public offering.

It’s a clinical-stage biopharmaceutical company focused on antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections.

“Leveraging our deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, we have built a proprietary purine nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases,” the company says.

And its lead candidate, AT-527, is a novel antiviral for treating patients infected with SARS-CoV-2, which causes COVID-19.

The offering comes via JPMorgan, Morgan Stanley, Evercore ISI and William Blair.

There’s a placeholder registration for $100M in shares. It’s expecting that its shares will trade on Nasdaq Global Market under the symbol AVIR.

It acknowledges competition from various companies working on the treatment of COVID-19, including Gilead Sciences (NASDAQ:GILD), Fujifilm Pharma, Ridgeback Biotherapeutics/Merck (NYSE:MRK), Regeneron (NASDAQ:REGN), Eli Lilly (NYSE:LLY), and others including Moderna, Inovio, Vir Biotechnology, Biogen, Johnson & Johnson, Pfizer, BioNTech, CanSino Biologics, AbbVie, Sanofi Pasteur, AstraZeneca, and Translate Bio.

Source Article Read the rest

Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Orphan Drug Dehydrated Alcohol Injection

Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Orphan Drug Dehydrated Alcohol Injection

Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application
for Orphan Drug Dehydrated Alcohol Injection

- Application Assigned a PDUFA Date of May 27, 2021

- Dehydrated Alcohol Injection Market Estimated to be Greater Than $100
Million Annually

- Application has Received Orphan Drug Designation for Methanol Poisoning

DEER PARK, Ill., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc
(Nasdaq: ETON), a specialty pharmaceutical company focused on developing and
commercializing innovative treatments for rare pediatric diseases, today
announced the U.S. Food and Drug Administration (FDA) has accepted for filing
the company’s new drug application (NDA) for dehydrated alcohol injection. The
application has been assigned a Prescription Drug User Fee Act (PDUFA) date of
May 27, 2021.

Eton’s application previously received orphan drug designation for the
treatment of methanol poisoning and is expected to receive seven years of
market exclusivity upon its approval.

The U.S. market for dehydrated alcohol injection is estimated to be greater
than $100 million annually and the drug is currently only supplied by a single
manufacturer^1.

About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
developing and commercializing innovative treatments for rare pediatric
diseases. The company currently owns or receives royalties from three
FDA-approved approved products, including ALKINDI® SPRINKLE, Biorphen®, and
Alaway® Preservative Free, and has six additional products in its late-stage
pipeline, including five that have been submitted to the FDA.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements
associated with the expected ability of Eton to undertake certain activities
and accomplish certain goals and objectives. These statements include but are
not limited to statements regarding Eton’s business strategy, Eton’s plans to
develop and commercialize its 
Read the rest